Alios Purchase Boosts J&J Anti-Infectives Game, Especially Hep C
This article was originally published in The Pink Sheet Daily
Executive Summary
A pair of promising preclinical nucleoside polymerase inhibitors for hepatitis C might be the driving force behind J&J’s $1.75 billion buyout of Alios, even though the privately held biotech’s most advanced candidate, ALS-8176, in Phase II for respiratory syncytial virus, also is a fit for J&J’s anti-infective strategy.
You may also be interested in...
Infectious Disease Companies Catch More Investors
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni
Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.